GIP
Glucose-dependent insulinotropic polypeptide, an incretin hormone with metabolic and adipose effects.
Glucose-dependent insulinotropic polypeptide (GIP), formerly called gastric inhibitory peptide, is an incretin hormone secreted by intestinal K-cells. It enhances glucose-dependent insulin secretion (like GLP-1) and has direct effects on adipose tissue including modulation of insulin sensitivity and lipid handling. The GIP receptor is the second receptor target of tirzepatide (Mounjaro / Zepbound) and retatrutide (LY-3437943). The mechanistic explanation for tirzepatide's larger metabolic effects vs. semaglutide cites GIP-mediated adipose-tissue effects on top of shared GLP-1 satiety / gastric emptying actions.
- GlossaryIncretin
Gut-derived hormones (GLP-1, GIP) that stimulate post-meal insulin secretion.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue
- ResearchRetatrutide 30 mg kit
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.
- ResearchRetatrutide 10 mg kit
Retatrutide 10 mg lyophilised vial kit — entry-point research presentation. Includes bac water, syringes, swabs.
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.